QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
Log in
NASDAQ:CKPT

Checkpoint Therapeutics Stock Forecast, Price & News

$3.35
-0.05 (-1.47 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.15
Now: $3.35
$3.47
50-Day Range
$1.99
MA: $2.49
$4.24
52-Week Range
$1.05
Now: $3.35
$4.50
Volume1.41 million shs
Average Volume583,464 shs
Market Capitalization$201.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Checkpoint Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.71 million
Book Value$0.34 per share

Profitability

Net Income$-24,710,000.00
Net Margins-1,664.75%

Miscellaneous

Employees7
Market Cap$201.13 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$3.35
-0.05 (-1.47 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

How has Checkpoint Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CKPT stock has increased by 151.9% and is now trading at $3.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Checkpoint Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Checkpoint Therapeutics
.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Checkpoint Therapeutics
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). The business earned $0.04 million during the quarter, compared to analyst estimates of $0.38 million. Checkpoint Therapeutics had a negative return on equity of 155.99% and a negative net margin of 1,664.75%.
View Checkpoint Therapeutics' earnings history
.

What price target have analysts set for CKPT?

3 analysts have issued 1-year price objectives for Checkpoint Therapeutics' shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Checkpoint Therapeutics' share price to reach $14.33 in the next year. This suggests a possible upside of 327.9% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics
.

Are investors shorting Checkpoint Therapeutics?

Checkpoint Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,770,000 shares, an increase of 18.8% from the August 15th total of 1,490,000 shares. Based on an average daily volume of 689,200 shares, the short-interest ratio is currently 2.6 days.
View Checkpoint Therapeutics' Short Interest
.

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Vaxart (VXRT), Aldeyra Therapeutics (ALDX) and Corbus Pharmaceuticals (CRBP).

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nuveen Asset Management LLC (0.32%), Charles Schwab Investment Management Inc. (0.20%), Bank of New York Mellon Corp (0.16%), Park Avenue Securities LLC (0.10%), UBS Group AG (0.03%) and Commonwealth Equity Services LLC (0.03%).
View institutional ownership trends for Checkpoint Therapeutics
.

Which major investors are selling Checkpoint Therapeutics stock?

CKPT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Checkpoint Therapeutics
.

Which major investors are buying Checkpoint Therapeutics stock?

CKPT stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Park Avenue Securities LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Commonwealth Equity Services LLC, and Virtu Financial LLC.
View insider buying and selling activity for Checkpoint Therapeutics
.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $3.35.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $201.13 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is www.checkpointtx.com.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.